Literature DB >> 2459776

Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope.

W N Burnette1, W Cieplak, V L Mar, K T Kaljot, H Sato, J M Keith.   

Abstract

Pertussis toxin (PTX) is a major virulence factor in whooping cough and can elicit protective antibodies. Amino acid residues 8 to 15 of PTX subunit S1 are important for the adenosine diphosphate-ribosyltransferase activity associated with the pathobiological effects of PTX. Furthermore, this region contains at least a portion of an epitope that elicits both toxin-neutralizing and protective antibody responses in mice. The gene encoding the S1 subunit was subjected to site-specific mutagenesis in this critical region. A mutant containing a single amino acid substitution (Arg9----Lys) had reduced enzymatic activity (approximately 0.02% of control) while retaining the protective epitope. This analog S1 molecule may provide the basis for a genetically detoxified PTX with potential for use as a component of an acellular vaccine against whooping cough.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459776     DOI: 10.1126/science.2459776

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  39 in total

1.  Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine.

Authors:  S M Loosmore; G R Zealey; H A Boux; S A Cockle; K Radika; R E Fahim; G J Zobrist; R K Yacoob; P C Chong; F L Yao
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.

Authors:  W N Burnette; J L Arciniega; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Pertussis toxin has eukaryotic-like carbohydrate recognition domains.

Authors:  K Saukkonen; W N Burnette; V L Mar; H R Masure; E I Tuomanen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

4.  Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity.

Authors:  W N Burnette; V L Mar; B W Platler; J D Schlotterbeck; M D McGinley; K S Stoney; M F Rohde; H R Kaslow
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

5.  Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.

Authors:  J L Arciniega; R D Shahin; W N Burnette; T D Bartley; D W Whiteley; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

6.  Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Authors:  P Boucher; H Sato; Y Sato; C Locht
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

7.  Biochemical and biological activities of recombinant S1 subunit of pertussis toxin.

Authors:  J T Barbieri; M Pizza; G Cortina; R Rappuoli
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

8.  Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.

Authors:  Jamie N Sutherland; Christine Chang; Sandra M Yoder; Michael T Rock; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

9.  Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit.

Authors:  T D Bartley; D W Whiteley; V L Mar; D L Burns; W N Burnette
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.

Authors:  C C Häse; L S Thai; M Boesman-Finkelstein; V L Mar; W N Burnette; H R Kaslow; L A Stevens; J Moss; R A Finkelstein
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.